This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Biotech Stock Mailbag: Xoma's Big Backers, FDA Approvals Contest

Stocks in this article: XOMAAFFYCHTPMAPPTLON

MAP is definitely a toss-up. I can see it going either way. It's very difficult to predict.

Of the three, I'd say Affymax is the easiest pick. I'll be really surprised if peginesatide isn't approved. I think most investors feel the same way.






Speaking of investor sentiment, let me run down the predictions for all the reader contestants in my FDA Drug Approval Contest:

MAP: 37% predict approval; 59% rejection; 4% no decision.

Affymax: 68% predict approval; 22% rejection; 10% no decision.

Chelsea: 53% approval; 43% rejection; 4% no decision.

A single contestant -- a biotech trader living in Texas who goes by the nickname "CBH" -- has a perfect 9-0 record in the contest so far. CBH predicts rejections for MAP's Levadex and Chelsea's Northera, and an approval for Affymax's peginesatide.

@Bullbear123 "@adamfeuerstin $TLON you were wrong again."

I was wrong about Talon Therapeutics (TLON). I didn't think the company would be capable of getting a positive vote for its leukemia drug Marqibo from Wednesday's FDA advisory pane. But that's what happened, even if the 7-4 vote (with two abstentions) in favor of Marqibo wasn't exactly a ringing endorsement.

I put abstentions in the "no" bucket, so the real vote was more like 7-6 recommending Marqibo's approval, which is even a weaker signal of support.

The FDA drug approval decision date for Marqibo is May 13.

To Talon's credit, the company did a nice job Wednesday framing Marqibo as a benefit for leukemia patients with no other medical options. Having Dr. Sue O'Brien, a respected oncologist from M.D. Anderson Cancer Center, advocating for Marqibo definitely helped sway some panel member votes. Smart strategy, Talon.

Working against Talon is Marqibo's "meh" efficacy, which was noted even by panel members who voted in favor of the drug. I didn't hear a single panel member effusively praise the drug. Most of the explanations for "yes" votes Wednesday were along the lines of, "Well, these patients are really sick, Marqibo may help them but probably won't hurt so I'll vote to recommend approval."

3 of 4

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 16,461.32 -153.49 -0.92%
S&P 500 1,927.11 -14.17 -0.73%
NASDAQ 4,382.8470 -36.6310 -0.83%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs